{
    "2018-04-18": [
        [
            {
                "time": "2018-04-01",
                "original_text": "Roche Hemophilia Drug Gets Breakthrough Therapy Designation",
                "features": {
                    "keywords": [
                        "Roche",
                        "Hemophilia",
                        "Drug",
                        "Breakthrough",
                        "Therapy",
                        "Designation"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "Gilead Sciences May Witness Significant Drop in Revenues in 2018",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Sciences",
                        "Drop",
                        "Revenues",
                        "2018"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "What Analysts Recommend for Gilead Sciences in April 2018",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommend",
                        "Gilead",
                        "Sciences",
                        "April",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Highlights",
                        "AbbVie",
                        "Berkshire",
                        "Hathaway",
                        "PepsiCo",
                        "BP",
                        "Twenty-First",
                        "Century",
                        "Fox"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "consumer goods",
                        "energy",
                        "media"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "Analysts’ Recommendations for AbbVie in April 2018",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "AbbVie",
                        "April",
                        "2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Present",
                        "Deutsche",
                        "Bank",
                        "Health",
                        "Care",
                        "Conference"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Duodopa",
                        "Creon",
                        "Synagis",
                        "Synthroid",
                        "Sevoflurane"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "5 Drug Stocks Poised to Surpass on Earnings This Quarter",
                "features": {
                    "keywords": [
                        "Drug",
                        "Stocks",
                        "Poised",
                        "Surpass",
                        "Earnings",
                        "Quarter"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}